New Global Study Finds: Sleep Apnea Patients Who Use CPAP Live Longer
ResMed Inc. (RMD)
Last resmed inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NYSE Investor Relations:
investors.resmed.com/investor-relations/default.aspx
Company Research
Source: GlobeNewswire
SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the publication of a landmark meta-analysis in The Lancet Respiratory Medicine, demonstrating that CPAP therapy significantly reduces the risk of death for people with obstructive sleep apnea (OSA). Analyzing data from over 1 million sleep apnea patients worldwide, the study provides the strongest evidence to date that CPAP therapy not only alleviates OSA symptoms but can also prolong life. OSA affects over one billion people worldwide,1 with over 80% of cases undiagnosed and untreated.2 This chronic sleep-related breathing disorder can impair daily functioning and has been associated with serious health conditions, including hypertension, diabetes, cardiovascular disease, and stroke.3 The study reinforces that untreated OSA is a major but modifiable risk factor for both all-cause and cardio
Show less
Read more
Impact Snapshot
Event Time:
RMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RMD alerts
High impacting ResMed Inc. news events
Weekly update
A roundup of the hottest topics
RMD
News
- Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- ResMed (NYSE:RMD) was given a new $260.00 price target on by analysts at Stifel Nicolaus. They now have a "hold" rating on the stock.MarketBeat
- ResMed (RMD): Revisiting Valuation After Recent Share Price Pullback [Yahoo! Finance]Yahoo! Finance
- ResMed (NYSE:RMD) was downgraded by analysts at Baird R W from a "strong-buy" rating to a "hold" rating.MarketBeat
- Tandem upgraded, Zimmer, ResMed downgraded as Baird previews MedTech in 2026 [Seeking Alpha]Seeking Alpha
RMD
Earnings
- 10/30/25 - Beat
RMD
Sec Filings
- 12/9/25 - Form 4
- 12/8/25 - Form 144
- 12/4/25 - Form 4
- RMD's page on the SEC website